Fujian Aonong Biological Technology Group Incorporation Limited

Shanghai Stock Exchange 603363.SS

Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio for the year ending December 31, 2023: -6.42

Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio is -6.42 for the year ending December 31, 2023, a -279.02% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio for the year ending December 31, 2022 was 3.59, a -49.27% change year over year.
Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio for the year ending December 31, 2021 was 7.07, a 330.67% change year over year.
Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio for the year ending December 31, 2020 was 1.64, a -11.49% change year over year.
Fujian Aonong Biological Technology Group Incorporation Limited Debt to Equity Ratio for the year ending December 31, 2019 was 1.85, a 21.60% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 603363.SS

Fujian Aonong Biological Technology Group Incorporation Limited

CEO	Mr. You Lin Wu
IPO Date	Sept. 26, 2017
Location	China
Headquarters	Guanyinshan Operation Center
Employees	8,759
Sector	Health Care
Industries Biotechnology Agriculture Pet Food

Description

Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig raising, raw materials trade, agricultural internet, bio-pharmaceutical, and other businesses in China and internationally. The company researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant feed, and other products; operates pig breeding farms; and engages in the pig slaughtering and processing activities. It also provides vaccines, veterinary drug preparations, micro ecological preparations, powders, premixes, oral liquids, additives, disinfectants, and other products, as well as creates intelligent breeding service platform. The company was founded in 2011 and is based in Xiamen, China.

Key trends

Past 5 years